megamillionsjackpotdrawing|众生药业(002317.SZ)：全资子公司获得普拉洛芬滴眼液药品注册证书

Gelonghui May 27 丨 Zhongsheng Pharmaceutical (002317)(002317megamillionsjackpotdrawing.SZ) announcedmegamillionsjackpotdrawingGuangdong Huanan Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, recently received the "Drug Registration Certificate" of Pralofen Eye Drops approved and issued by the State Food and Drug Administration.

Pranoprofen belongs to a propionic acid non-steroidal anti-inflammatory drug. Its mechanism of action is to mainly inhibit cyclooxygenase (COX) activity, block the synthesis of eicosaponic acid derivatives, inhibit the synthesis of prostaglandins, and relieve inflammatory reactions. The indication for pralofen eye drops is symptomatic treatment of inflammation of the external eye and anterior segment (blepharitis, conjunctivitis, keratitis, scleritis, superficial scleritis, iridocyclitis, postoperative inflammation).

The company's product Pralofen Eye Drops has been approved for marketing under Category 4 of the Chemical Drug Registration Classification, marking that this product is regarded as having passed the consistency evaluation of chemical generic drugs.

According to the MinineNet database, the sales of pralofen eye drops in urban public hospitals in China from 2021 to 2023 were RMB 567.42 million, RMB 525.77, and RMB 637.49 million respectively.

Tags：

Article Copyright Statement: Unless otherwise specified, all articles are jiliasia16 com original. Reproduction or reproduction should be in the form of hyperlinks and indicate the source.